Bruce Morimoto
Head of Drug Development Fuku Biotech
Seminars
Thursday 5th February 2026
Roundtable Discussion: Digital Wearable Sensors to Provide Continuous, Objective Motor Data & Unlock Faster, Leaner Parkinson’s Trials as Primary Endpoints
2:00 pm
- Capturing wrist worn and smartphone sensor streams that continuously log tremor, bradykinesia, and gait, supplying objective high frequency data that can shrink sample sizes and sharpen signal detection
- Highlighting the first regulated Parkinson’s study to use a digital movement biomarker as its primary outcome, setting a clear regulatory precedent that boosts sponsor confidence to adopt wearables in future trials
Wednesday 4th February 2026
Panel Discussion: Ushering in a New Era of Disease-Modifying Therapies in AD & PD – Beyond Amyloid & α-Synuclein
8:30 am
- Exploring emerging mechanisms such as mitochondrial stress, ferroptosis, and microglial TREM2 to diversify therapeutic strategies and expand opportunities
- Evaluating how mixed-modality combinations may outperform single antibodies, offering more robust and durable disease-modifying potential
- Implementing biomarker panels to de-risk first-in-human trials, enabling smarter patient selection and stronger regulatory confidence
Thursday 5th February 2026
Panel Discussion: Patient Perspectives in Neurodegeneration: Shaping the Future of Alzheimer’s & Parkinson’s Drug Development
9:00 am
- Hear directly from individuals living with Alzheimer’s and Parkinson’s alongside leading foundations, offering a unified view of lived experience and scientific context
- Explore real-world treatment challenges, clinical trial barriers, and the outcomes that matter most to patients across both diseases
- Gain actionable, patient-driven insights to inform more inclusive, meaningful, and effective drug development and trial design
Thursday 5th February 2026
Panel Discussion: Bridging Innovation & Investment: De-Risking Disease-Modifying Neurodegenerative Therapies to Secure Investor Backing
4:30 pm
- How important is it to present rigorously validated biology and clear platform expansion potential, rather than a single asset story, when seeking investment in disease modifying Alzheimer’s or Parkinson’s therapies?
- Is a biomarker driven proof of concept within roughly 24 months now viewed as the standard benchmark for funding decisions in neurodegenerative drug development?
- To what extent does a pipeline that hedges risk through multiple mechanisms, such as combining blood–brain barrier shuttle antibodies with gene or small molecule therapies, shape investment appetite in this space?
Thursday 5th February 2026
Chair’s Opening Remarks
8:30 am
Wednesday 4th February 2026
Chair’s Opening Remarks
8:25 am
Thursday 5th February 2026
Chair’s Closing Remarks & End of Conference
5:00 pm
Wednesday 4th February 2026
Chair’s Closing Remarks
5:00 pm
Thursday 5th February 2026
Chair:
Thursday 5th February 2026
Chair:
